Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Haploidentisk donor CMV-spesifikk CTL for å behandle CMV-reaktivering eller infeksjon etter fast organ og HCT

21. september 2026 oppdatert av: Sumithira Vasu

Pilotstudie av haploidentiske donorcytomegalovirus (CMV) spesifikke cytotoksiske T-lymfocytter (CTL) for å behandle CMV-reaktivering eller infeksjon etter solid organ- og hematopoietisk stamcelletransplantasjon (HCT)

This trial studies the side effects and how well allogeneic cytomegalovirus-specific cytotoxic T lymphocytes (donor cytomegalovirus [CMV] specific cytotoxic T-lymphocytes [CTLs]) or allogeneic adenovirus-specific cytotoxic T lymphocytes (donor adenovirus-specific [AdV] specific CTLs) work in treating CMV or AdV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant. White blood cells from donors may be able to kill cancer cells in patients with cytomegalovirus or adenovirus that has come back after a stem cell or solid organ transplant.

Studieoversikt

Detaljert beskrivelse

PRIMARY OBJECTIVE I. Assess the safety and feasibility of administering virus specific-CTLs from haploidentical donors in transplant patients both solid organ transplantation (SOT) and hematopoietic cell transplantation (HCT) with CMV/AdV infection despite standard therapy.

OUTLINE:Patients are assigned to 1 of 2 Cohorts.

COHORT A: Patients receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes intravenously (IV). Patients undergo blood, urine, saliva, cerebrospinal fluid (CSF), and bronchoalveolar fluid sample collection on the trial.

COHORT B: Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Patients undergo blood, urine, saliva, CSF, and bronchoalveolar fluid sample collection on the trial.

After completion of study treatment, participants are followed up at 1 year.

Studietype

Intervensjonell

Registrering (Antatt)

20

Fase

  • Tidlig fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Ohio
      • Columbus, Ohio, Forente stater, 43205
        • Rekruttering
        • Nationwide Children's Hospital
        • Ta kontakt med:
          • Chris Ouellette, MD
        • Ta kontakt med:
      • Columbus, Ohio, Forente stater, 43210
        • Suspendert
        • Ohio State University Comprehensive Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

1 år til 85 år (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients must have solid organ transplant or have received allogeneic hematopoietic stem cell transplant.

  • • Cohort A (CMV): Must have documented CMV disease or reactivation, as by:

    • Viremia as detected by quantitative polymerase chain reaction (PCR) (> 500 IU/ml) in the peripheral blood requiring treatment OR

    • High risk for antiviral failure due to history of recurrent CMV reactivations or evidence of antiviral drug resistance, OR

    • Unable to tolerate antiviral drugs due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury

      • Cohort B (AdV): Must have documented AdV infection or reactivation, as by:

    • Symptomatic subject with any detectable viral load in blood, OR

    • Symptomatic subject with qualitative AdV detection in compartment of current symptomatology, including stool, urine, and/or other specimens (bronchoalveolar lavage (BAL), nasal swab, CSF, etc.), irrespective of blood viral load, OR

    • New, persistent, and/or worsening AdV-related symptoms, signs, and/or markers of end organ compromise while receiving antiviral therapy (ie cidofovir), OR

    • Asymptomatic with a viral load > 1000 copies/ml in peripheral blood, OR

    • Unable to tolerate antiviral treatment due to renal toxicity, bone marrow suppression, transfusion dependent anemia and thrombocytopenia or neutropenia requiring growth factor support or other related organ injury

      • Karnofsky (age > 16 years) or Lansky performance score > 70 (age < 16)
      • Available seropositive haploidentical or matched donor who is without evidence of infection that would otherwise preclude donation
      • Negative pregnancy test in female patients if applicable (childbearing potential, has not received a full-intensity conditioning regimen
      • Written informed consent and/or signed assent line from patient, parent or guardian
      • DONOR
      • Human leukocyte antigen (HLA)-haploidentical or full-match to the patient as determined by institutional standards
      • Cohort A: CMV seropositive, defined as detection of serum CMV immunoglobulin G (IgG)
      • Cohort B: AdV seropositive, defined as detection of serum AdV IgG
      • Age 18 or over
      • Meet donor eligibility or suitability according to institutional standards. If the donor is deemed ineligible according to Foundation for the Accreditation of Cellular Therapy (FACT) standards, but is suitable for donation per institutional standards, the donor will be eligible for the protocol

Exclusion Criteria:

  • Receipt of anti-thymocyte globulin (ATG), alemtuzumab, or other T-cell depleting agents within 21 days of screening for enrollment.

  • Receipt of > 0.5mg/kg/day of prednisone or steroid equivalent at the time of enrollment. Stable GVHD is permitted as long as patients are on stable dose steroids of less than or equal to 0.5 mg/kg/day of prednisone or steroid equivalent.

  • Evidence of uncontrolled infection as follows:

    • Bacterial infections - patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment.
    • Fungal infections - patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.
    • Patients with hemodynamic instability attributable to bacterial sepsis or new symptoms, worsening physical signs or radiographic findings attributable to concomitant bacterial or fungal infection are excluded. Patients who require ventilator support for CMV pneumonitis are not excluded. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
  • Receipt of donor lymphocyte infusion (DLI) within 28 days.

  • Patients with active acute graft versus host disease (GvHD) grades II-IV requiring > 0.5 mg/kg/day of prednisone or steroid equivalent or T-cell depleting immunosuppression.

  • Acute graft rejection in solid organ transplantation requiring augmented immunosuppression with T-cell depleting agents or steroids as mentioned above.

  • Active and uncontrolled relapse of malignancy.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment (CMV-specific CTLs)

Participants receive allogeneic cytomegalovirus-specific cytotoxic T lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.

Given intravenously

Eksperimentell: Treatment (AdV-specific CTLs)

Patients receive allogeneic adenovirus-specific cytotoxic T Lymphocytes IV. Participants with persistent infection are eligible for second infusion after 28 days.

Given intravenously

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Gjennomførbarhet definert som å identifisere en passende donor innen 4 uker og oppfylle minimum T-celledoser i sluttproduktet
Tidsramme: Inntil 1 år
Inntil 1 år
Incidence of adverse events defined by the National Cancer Institute Common Terminology Criteria for Adverse Events 4.0
Tidsramme: Up to 30 days post infusion

Measured as the proportion of patients with acute (a) graft versus host disease (GvHD) grades III-IV or graft rejection/failure within 30 days of the last dose of cytotoxic T-lymphocytes (CTLs) or grades 3-5 infusion-related adverse events within 7 days of the last does of CTLs or grades 4-5 non-hematological adverse events within 30 days of the last dose of CTLs and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities. Will be calculated by dividing by all evaluable patients and the corresponding 95% confidence intervals will be calculated.

Up to 30 days post infusion

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Persistens av infunderte CTL-er som målt ved T-celle-genomorganisering og effekter på kliniske tegn på virusinfeksjon
Tidsramme: Inntil 1 år
Inntil 1 år
Effekter av cytomegalovirus (CMV) spesifikk-CTL på viral belastning vurdert ved ukentlig revers transkriptase-polymerase kjedereaksjon
Tidsramme: Inntil 1 år
Inntil 1 år
Klinisk respons på CTL-infusjoner
Tidsramme: Ved 6 uker og 3 måneder
Ved 6 uker og 3 måneder
Antall deltakere med behandlingsrelaterte bivirkninger vurdert av CTCAE v4.0".
Tidsramme: Inntil 1 år
Inntil 1 år
Antiviral activity defined as response to viral load
Tidsramme: At day 28

Complete response, partial response, stable disease or progression will be defined and proportion of each outcome will be calculated.

At day 28
Overall survival
Tidsramme: From last CTL infusion till death, assessed at 6 and 12 months

Kaplan-Meier survival function will be used to estimate the survival probability.

From last CTL infusion till death, assessed at 6 and 12 months
Risk for chronic GVHD
Tidsramme: At 6 and 12 months post CTL infusion

Survival analysis method will be applied. Time to chronic GVHD will be defined from time of the last CTL infusion to the onset of chronic GVHD, or the last clinical assessment date if no chronic GVHD. Cumulative incidence of chronic GVHD at 6 and 12 months will be estimated.

At 6 and 12 months post CTL infusion
Systemic infections
Tidsramme: Within 6 months of CTL infusion

Will be reported by etiologic agent, site of disease, date of onset, and severity.

Within 6 months of CTL infusion
Secondary graft failure
Tidsramme: 30 days post-CTL infusion

Proportion of secondary graft failure for both populations will be assessed at 30 days post CTL infusion will be calculated and 95% confidence intervals will be estimated accordingly.

30 days post-CTL infusion
Viral reactivations
Tidsramme: Up to 6 months

Proportion of viral reactivations within 6 months will be calculated and 95% confidence intervals will be estimated accordingly.

Up to 6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Sumithira Vasu, MBBS, Ohio State University Comprehensive Cancer Center

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

7. november 2020

Primær fullføring (Antatt)

20. mars 2027

Studiet fullført (Antatt)

20. juni 2027

Datoer for studieregistrering

Først innsendt

13. august 2018

Først innsendt som oppfylte QC-kriteriene

7. september 2018

Først lagt ut (Faktiske)

11. september 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. mars 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • OSU-17199
  • NCI-2018-01412 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere